From Monday, September 16th, the ENYO Pharma teams will invest new premises in the BIOPARC which is being set up in LYON 8th. This is the opportunity to expand and benefit from the emulation that BIOPARC will create.
ENYO Pharma takes part to the research against Hepatitis B with the development of its FXR agonist EYP001 and support the research is this field by becoming one of the sponsor of the Hep B Foundation which is “a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide”
ENYO Pharma will move-in to the new Biosera BioParc Building in Laënnec. It will be a great opportunity as we will be neighbours with Edelris, Erytech Pharma and AB Science. Some CEO, Jean-Yves ORTHOLAND (Edelris), Gil BEYEN (Erytech Pharma) and Jacky VONDERSCHER (ENYO Pharma) recently visited the building under construction.
MIMESIS NEWSLETTER #4, December 2018
After two years, ENYO Pharma’s EU funded MIMESIS project was a real success and has delivered several promising new drug development starting points most significantly for RSV and ICD.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”.
ENYO Pharma’s VP Corporate Development & Strategy Nicolas Guyon-Gellin is participating today in “La Matinale Santé” organized by Bpifrance in Paris, France. Bpifrance finances businesses – at every stage of their development – through loans, guarantees and equity investments, but also offers extra financial services. During this event, Nicolas will talk about Bpifrance’s financing and investments actions in the health sector and the role of the Large Venture Fund. This will be a great opportunity to discuss how Bpifrance is currently supporting ENYO Pharma to pursue its growth and development.